

B1/9

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 December 2005 (29.12.2005)

PCT

(10) International Publication Number
WO 2005/122790 A1

(51) International Patent Classification⁷: A23L 1/29, 1/30

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/NL2004/000444

(22) International Filing Date: 22 June 2004 (22.06.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant (for all designated States except US): N.V. NUTRICIA [NL/NL]; Eerste Stationsstraat 186, NL-2712 HM Zoetermeer (NL).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): VAN TOL, Eric, A., F. [NL/NL]; Roemer Visscherstraat 62, NL-6824 MZ Arnhem (NL). WILLEMSSEN, Linette, Eustachia, Marla [NL/NL]; Croesestraat 94, NL-3522 AJ Utrecht (NL). KOETSIER, Marleen, Antoinette [NL/NL]; Ankerstraat 96, NL-8161 XJ Epe (NL). BEERMANN, Christopher [DE/DE]; Bahnhofstrasse 120a, 61267 Neu-Anspach (DE). STAHL, Bernd [DE/DE]; Breslauer Strasse 77, 61191 Rosbach (DE).

(74) Agent: VAN WESTENBRUGGE, Andries; Nederlandse Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/122790 A1

(54) Title: IMPROVEMENT OF INTESTINAL BARRIER INTEGRITY

(57) Abstract: The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

WO 2005/122790

PCT/NL2004/000444

1

IMPROVEMENT OF INTESTINAL BARRIER INTEGRITY**FIELD OF THE INVENTION**

The present invention relates to a method for improving intestinal barrier integrity and
5 a composition suitable for use in such method.

BACKGROUND OF THE INVENTION

The gastrointestinal epithelium normally functions as a selective barrier permitting the absorption of nutrients, electrolytes and water and preventing the exposure to dietary
10 and microbial antigens, including food allergens. The gastrointestinal epithelium limits the passage of antigens to the systemic circulation, that may be causing inflammatory reactions, e.g. allergic reactions. As the incidence of allergy, particularly food allergy, is increasing, many research groups search for (preventive) cures for these ailments.

- 15 EP1272058 describes a composition containing indigestible oligosaccharides for improving tight junction to reduce intestinal permeability and reducing allergic reaction. The composition may comprise LC-PUFA's (long chain-polyunsaturated fatty acids).
- 20 EP 745001 describes a combination of indigestible oligosaccharides and n-3 and n-6 fatty acids for treatment ulcerative colitis.

Usami et al (Clinical Nutrition 2001, 20(4): 351-359) describe the effect of eicosapentaenoic acid (EPA) on tight junction permeability in intestinal monolayer
25 cells. In their hands, EPA was found to increase permeability, indicating that EPA is unsuitable to improve intestinal barrier integrity.

The prior art formulations are not optimally suited for improving barrier integrity.

30 **SUMMARY OF THE INVENTION**

The present invention provides a combination of selected long chain polyunsaturated fatty acids (LC-PUFA's) and selected oligosaccharides. The present combination of LC-PUFA's and oligosaccharides effectively improves barrier integrity, by

WO 2005/122790

PCT/NL2004/000444

2

synergistically improving intestinal permeability and mucus production, and is particularly suitable for improving barrier integrity in human infants.

It was surprisingly found that selected LC-PUFA's effectively reduce epithelial
5 paracellular permeability. In contrast to what Usami et al (Clinical Nutrition 2001,
20(4): 351-359) have reported, the present inventors found that C18 and C20
polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA) and arachidonic acid (ARA), are capable of effectively reducing intestinal
tight junction permeability.

10

In addition to the LC-PUFAs, the present composition contains oligosaccharides. The
selected oligosaccharides improve the barrier integrity by stimulating the production of
the mucus, which results in an increased mucus layer thickness. It is believed this effect
is caused by the effects of the distinct oligosaccharides on the short chain fatty acid
15 (SCFA) production. Hence, when enterally administered to a mammal, the present
combination of LC-PUFA and indigestible oligosaccharides synergistically improve
barrier integrity and/or synergistically reduce intestinal permeability by simultaneous
reduction of tight junction permeability and stimulation of mucus production.

20 In a further aspect, the present composition improves the quality of the intestinal mucus
layer. The mucus layer comprises mucins. Mucins are high molecular mass
glycoproteins that are synthesized and secreted by goblet cells. They form a gel-like
layer on the mucosal surface, thereby improving barrier integrity. The mucus layer
comprises different types of mucins, e.g. acid, neutral and sulphonated mucins. An
increased heterogeneity of the mucus layer is believed to improve barrier functionality.
25

The present composition preferably comprises at least two different oligosaccharides,
which influence the mucosal architecture and advantageously influence mucin
heterogeneity in the mucus layer, either directly or by changing the intestinal flora.
30 Each different selected oligosaccharide is believed to have a different effect on mucus
quantity and quality. Moreover, the two distinct oligosaccharides are also able to
stimulate quality of mucus as reflected by the degree of sulphation through their
synergistic stimulation of SCFA production. It was surprisingly found by the present

WO 2005/122790

PCT/NL2004/000444

3

inventors that a mixture of two different oligosaccharides according to the present invention synergistically stimulates acetate production. It was also found by the present inventors mucus production is dependent on acetate production.

- 5 The present composition is preferably further improved by providing both long- and short-chain oligosaccharides. The supply of different chain lengths results in stimulation of mucus production in different parts of the ileum and colon. The short chain oligosaccharides (typically with a degree of polymerisation (DP) of 2,3,4 or 5) stimulate mucin production in the proximal colon and/or distal ileum, while the
10 10 oligosaccharides with longer chain lengths (preferably with a degree of polymerisation (DP) of more than 5 up to 60) are believed to stimulate mucin production in the more distal parts of the colon.

Even further improvements can be achieved by providing the at least two different
15 15 oligosaccharides both as short-chain and long-chain oligosaccharides. These preferred embodiments all contribute to further improved barrier integrity throughout the ileum and/or colon.

Furthermore, it was surprisingly found that EPA, DHA and ARA were able to reduce
20 20 the harmful effects of interleukin 4 (IL-4) on intestinal permeability. IL-4 is a cytokine which is secreted in increased amounts by mucosal T-cells in certain patients and induces intestinal permeability. Hence the present invention also provides for a method for the treatment and/or prevention of diseases wherein intestinal IL-4 concentration is increased, such as allergy, particularly atopic dermatitis.

25

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a nutritional composition comprising:

- a) EPA, DHA and ARA, wherein the content of long chain polyunsaturated fatty acid with 20 and 22 carbon atoms does not exceed 15 wt.% of the total fat content; and
30 30 b) at least two distinct oligosaccharides, wherein the two distinct oligosaccharides have a homology in monose units below 90 %.

This composition can be advantageously used in a method for stimulating intestinal barrier integrity, said method comprising administering to a mammal said composition.

WO 2005/122790

PCT/NL2004/000444

Polyunsaturated fatty acids

The present inventors surprisingly found that eicosapentaenoic acid (EPA, n-3), docosahexaenoic acid (DHA, n-3) and arachidonic acid (ARA, n-6) effectively reduce 5 intestinal tight junction permeability. Hence the present composition, which is particularly suitable for improving intestinal barrier integrity, comprises EPA, DHA and ARA.

The present inventors found that lower concentration of LC-PUFA's, were effective in 10 reducing tight junction permeability (see Examples vs. Usami et al). Hence, the content of LC-PUFA with 20 and 22 carbon atoms in the present composition, preferably does not exceed 15 wt.% of the total fat content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.% of the total fat content. Preferably the present composition comprises at least 0.1 wt.%, preferably at least 0.25 wt, more preferably at 15 least 0.5 wt.%, even more preferably at least 0.75 wt.% LC-PUFA with 20 and 22 carbon atoms of the total fat content. For the same reason, the EPA content preferably does not exceed 5 wt.% of the total fat, more preferably does not exceed 1 wt.%, but is preferably at least 0.05 wt%, more preferably at least 0.1 wt.% of the total fat. The DHA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 20 wt.%, but is at least 0.1 wt% of the total fat. As ARA was found to be particularly effective in reducing tight junction permeability, the present composition comprises relatively high amounts, preferably at least 0.1 wt.%, even more preferably at least 0.25 wt.%, most preferably at least 0.5 wt.% of the total fat. The ARA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.% of the total fat. In the 25 present ARA containing enteral composition, EPA and DHA are advantageously added to balance the action of ARA, e.g. reduce the potential proinflammatory action of ARA metabolites. Excess metabolites from ARA may cause inflammation. Hence, the present composition preferably comprises ARA, EPA and DHA, wherein the weight ratio ARA/DHA preferably is above 0.25, preferably above 0.5, even more preferably above 1. The ratio is preferably below 25. The weight ratio ARA/EPA is preferably 30 between 1 and 100, more preferably between 5 and 20.

WO 2005/122790

PCT/NL2004/000444

5

The present composition preferably comprises between 5 and 75 wt.% polyunsaturated fatty acids based on total fat, preferably between 10 and 50 wt.%.

If the present composition is used as an infant formula (e.g. a method for feeding an infant, said method comprising administering the present composition to an infant), the content of LC-PUFA, particularly the LC-PUFA with 20 and 22 carbon atoms, preferably does not exceed 3 wt.% of the total fat content as it is desirable to mimic human milk as closely as possible. For the same reason, the omega-3 LC-PUFA content preferably does not exceed 1 wt.% of the total fat content; the omega-6 LC-PUFA content preferably does not exceed 2 wt.% of the total fat content; the ARA (omega-6) content is preferably below 1 wt.% of the total fat content; and/or the weight ratio EPA/DHA is preferably 1 or lower, more preferably below 0.5.

The LC-PUFA with 20 and 22 carbon atoms may be provided as free fatty acids, in triglyceride form, in phospholipid form, or as a mixture of one of more of the above. The present composition preferably comprises at least one of ARA and DHA in phospholipid form.

The present nutritional composition preferably also provides omega-9 (n-9) fatty acid (preferably oleic acid, 18:1), to provide sufficient nutrition. Preferably the present composition provides at least 15 wt.% n-9 fatty acid based on the weight of the total fatty acids, more preferably at least 25 wt%. The content of n-9 fatty acids is preferably below 80 wt.%.

25 Oligosaccharides

Suitable oligosaccharides according to the invention are saccharides which have a degree of polymerisation (DP) of at least 2 monose units, which are not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach), but which are fermentable by the human intestinal flora. The term monose units refers to units having a closed ring structure, preferably hexose, e.g. the pyranose or furanose forms. The degree of polymerisation of the oligosaccharide is typically below 60 monose units, preferably below 40, even more preferably below 20.

WO 2005/122790

PCT/NL2004/000444

The present composition comprises at least two different oligosaccharides, wherein the oligosaccharides have a homology in monose units below about 90%, preferably below 50%, even more preferably below 25%, even more preferably below 5%. The term
5 "homology" as used in the present invention is the cumulative of the percentage of same monose units in the different oligosaccharides. For example, oligosaccharide 1 (OL1) has the structure fruc-fruct-glu-gal, and thus comprises 50% fruc, 25% gal and 25% glu. Oligosaccharide 2 (OL2) has the structure fruc-fruc-glu, and thus comprises 66% fruc, 33% glu. The different oligosaccharides thus have a homology of 75% (50%
10 fruc + 25% glu).

In a preferred embodiment, the present composition comprises galactooligosaccharides and at least one selected from the group consisting of fructooligosaccharides and inulin.

15 Each of the present oligosaccharides preferably comprises at least 66%, more preferably at least 90% monose units selected from the group consisting of mannose, arabinose, fructose, fucose, rhamnose, galactose, β -D-galactopyranose, ribose, glucose, xylose, uronic acid and derivatives thereof, calculated on the total number of monose units contained therein.

20 According to a further embodiment at least one of the oligosaccharides of the present composition is selected from the group consisting of fructans, fructooligosaccharides, indigestible dextrins galactooligosaccharides (including transgalactooligosaccharides), xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannooligo-
25 saccharides, fucooligosaccharides, acidic oligosaccharides (see below, e.g. uronic acid oligosaccharides such as pectin hydrolysate) and mixtures thereof. Preferably the present composition comprises at least one, preferably at least two, of the oligosaccharides selected from the group consisting of fructooligosaccharides or inulin, galactooligosaccharides and pectin hydrolysate.

30 For good mucus quantity and quality, the present composition preferably comprises at least one oligosaccharide, which comprises at least 66% galactose or fructose as a monose unit. In a preferred embodiment the composition comprises at least one

WO 2005/122790

PCT/NL2004/000444

7

- oligosaccharide which comprises at least 66% galactose as a monose unit and at least one oligosaccharide which comprises at least 66% fructose as a monose unit. In a particularly preferred embodiment, the present composition comprises galactooligosaccharide and an oligosaccharide selected from the group consisting of
5 fructooligosaccharides and inulin. Fructooligosaccharides stimulate sulfomucin production in the distal colon of human flora-associated rats (Kleessen et al, (2003) Brit J Nutr 89:597-606) and galactooligosaccharides stimulate the acid mucin production (Meslin et al, Brit. J.Nutr (1993), 69: 903-912)).
10 For further improvement of mucus layer thickness over the whole area of the colon, at least 10 wt.% of the oligosaccharides in the present composition has a DP of 2 to 5 (i.e. 2, 3, 4 and/or 5) and at least 5 wt.% has a DP of 10 to 60. Preferably at least 50 wt.%, more preferably at least 75 wt.% of the oligosaccharides have a DP of 2 to 9 (i.e. 2, 3, 4, 5, 6, 7, 8, and/or 9), because these are believed to work throughout the ileum and
15 proximal and middle parts of the colon and because the weight percentage of oligosaccharides that needs to be incorporated in the composition to achieve the desired effect is reduced.

Preferably the weight ratios:

- 20 a. (oligosaccharides with DP 2 to 5) : (oligosaccharides with DP 6,7,8 and/or 9) > 1;
and
b. (oligosaccharides with DP 10 to 60) : (oligosaccharides with DP 6,7,8 and/or 9) > 1
are both above 1.
25 Preferably both weight ratios are above 2, even more preferably above 5.

For even further improvement of mucus layer thickness and quality over the whole area of the colon, preferably each of the at least two different oligosaccharides are provided in different chain lengths, preferably at least 10 wt.% of each oligosaccharide based on
30 the total weight of the respective oligosaccharide has a DP of 2 to 5 (i.e. 2, 3, 4 and/or 5) and at least 5 wt.% has a DP between 10 and 60. Preferably at least 50 wt.%, more preferably at least 75 wt.% of the oligosaccharide based on the total weight of that

WO 2005/122790

PCT/NL2004/000444


8

oligosaccharides has a DP between 2 and 10, because these are believed to work throughout in the ileum and proximal and middle parts of the colon.

Acidic oligosaccharides

- 5 To further improve barrier integrity, the present composition preferably includes acidic oligosaccharides with a DP between 2 and 60. The term acid oligosaccharide refers to oligosaccharides comprising at least one acidic group selected from the group consisting of N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group. The acidic
10 oligosaccharide preferably comprises uronic acid units (i.e. uronic acid polymer), more preferably galacturonic acid units. The acid oligosaccharide may be a homogeneous or heterogeneous carbohydrate. Suitable examples are hydrolysates of pectin and/or alginic acid. In the intestinal tract, the uronic acid polymers are hydrolysed to uronic acid monomers, which stimulate production of intestinal acetate, which in turn stimulates
15 intestinal mucus secretion (Barcelo et al., Gut 2000; 46:218-224).
Preferably the acid oligosaccharide has the structure I below, wherein the terminal hexose (left) preferably comprises a double bond. The hexose units other than the terminal hexose unit(s) are preferably uronic acid units, even more preferably galacturonic acid units. The carboxylic acid groups on these units may be free or
20 (partly) esterified, and preferably at least 10% is methylated (see below).

Structure I: Polymeric acid oligosaccharide



30

wherein:

R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy; and

WO 2005/122790

PCT/NL2004/000444

9

- at least one selected from the group consisting of R₂, R₃, R₄ and R₅ represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R₂, R₃, R₄ and R₅ representing hydroxy and/or hydrogen. Preferably one selected from the group
- 5 consisting of R₂, R₃, R₄ and R₅ represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group or phosphoric acid group, and the remaining represent hydroxy and/or hydrogen. Even more preferably one selected from the group consisting of R₂, R₃, R₄ and R₅ represents free or esterified carboxylic acid and the remaining of R₂, R₃, R₄ and R₅ representing
- 10 hydroxy and/or hydrogen; and
- n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit. Suitably n is an integer between 1-5000. Preferably the hexose unit(s) is a uronic acid unit.
- Most preferably R₁, R₂ and R₃ represent hydroxy, R₄ represent hydrogen, R₅ represents
- 15 carboxylic acid, n is any number between 1 and 250, preferably between 1 and 10 and the hexose unit is galacturonic acid.

The detection, measurement and analyses of the preferred acid oligosaccharides as used in the present method are given in applicants earlier patent application relating to acid

20 oligosaccharides, i.e. WO 0/160378.

For stimulation improvement of mucus layer thickness over the whole area of the colon, the present composition preferably comprises at least 10 wt.% acid oligosaccharides with a DP of 2 to 5 (i.e. 2, 3, 4 and/or 5) and at least 5 wt.% acid

25 oligosaccharides with a DP between 10 and 60, said wt.% being based on the total weight of the oligosaccharides.

The acid oligosaccharides used in the invention are preferably prepared from pectin, pectate, alginate, chondroitine, hyaluronic acids, heparine, heparane, bacterial

30 carbohydrates, sialoglycans, fucoidan, fucooligosaccharides or carrageenan, more preferably from pectin and/or alginate.

WO 2005/122790

PCT/NL2004/000444

10

Content of oligosaccharide

When in ready-to-feed liquid form, the present composition preferably comprises 0.1 to 100 grams indigestible oligosaccharide per liter, more preferably between 0.5 and 50 grams per liter even more preferably between 1 and 25 grams per liter. A too high content of oligosaccharides may cause discomfort due to excessive fermentation, while a very low content may result in an insufficient mucus layer.

The weight ratio of the at least two different oligosaccharides is preferably between 1 and 10, more preferably between 1 and 5. These weight ratios stimulate mucin production of different types at different sites in the intestine optimally.

10

The oligosaccharide is preferably included in the present composition according to the invention in an amount exceeding 0.1 wt.%, preferably exceeding 0.2 wt.%, more preferably exceeding 0.5 wt.% and even more preferably exceeding 1 wt.% based on the total dry weight of the composition. The present composition preferably has an oligosaccharide content below 20-wt.%, more preferably below 10-wt.% even more preferably below 5-wt.%.

20
15

Addition of nucleotides and/or nucleosides to the present composition further improves gut mucosal barrier function, particularly as it inhibits and/or or reduces the incidence of bacterial translocation and decreases intestinal injury. Hence, the present composition preferably also comprises between 1 and 500 mg nucleosides and/or nucleotides per 100 gram of the dry formula, even more preferably between 5 and 100 mg.

25
30Application

The present composition can be advantageously used in a method for improving barrier integrity in mammals, particularly humans. The present composition can also be advantageously used in a method for the treatment or prevention of diseases associated with reduced barrier integrity, said method comprising administering to a mammal the present composition. The present composition is preferably administered orally.

For the ill and infants, the present composition is preferably combined with complete nutrition, including protein, carbohydrate and fat. The present composition is

WO 2005/122790

PCT/NL2004/000444

11

advantageously administered to infants with the age between 0 and 2 years. The composition may be administered to patients which suffer from an impaired barrier integrity and healthy patients. The present composition is advantageously used in a method for providing the nutritional requirements of a premature infant (an infant born
5 before 37 weeks gestation).

The present composition can also be advantageously used in a method for treatment and/or prevention of intestinal damage by administering the present composition to the patient prior to or after a medical treatment, which may cause intestinal damage. Such
10 medical treatment may for example be surgery or enteral medicine treatment (e.g. antibiotic, analgesic, NSAID, chemotherapeutic agents etc).

The present composition can also be advantageously used to treat or prevent diseases wherein intestinal barrier disruption is underlying the development of the course of the
15 disease, e.g. in a method for the treatment or prevention of chronic inflammatory diseases, particularly inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, pancreatitis, hepatitis, arthritis or diabetes. Furthermore, the invention can be used in a method for providing nutrition to patients which have undergone or are undergoing abdominal surgery and patients that experience
20 postoperative dysfunction of the gut and/or malnourished patients.

In a further embodiment of the invention the present composition is advantageously administered to patients suffering from acquired immune deficiency syndrome (AIDS) and/or patients which are infected with the human immunodeficiency virus (HIV), e.g.
25 in a method for the treatment of AIDS and/or HIV infection. Said method comprises the oral administration of the present composition, preferably combined with nutrients selected from the group consisting of carbohydrate, protein and fat.

Furthermore, the invention can also be used to treat or prevent complications resulting
30 from reduced barrier integrity, particularly in a method for the treatment and/or prevention of diarrhea, particularly infant diarrhea. Due to the reduced incidence in infant diarrhea, the present composition can also be advantageously used to reduce diaper rash.

WO 2005/122790

PCT/NL2004/000444

12

Administering the present composition reduces passage of dietary and microbial antigens, particularly food allergens, from the intestinal lumen into the mucosal or systemic circulation, and hence can be advantageously used in a method for the
5 treatment or prevention of allergy and/or allergic reaction, particularly in a method for the treatment or prevention of food allergy, e.g. allergic reaction resulting from the ingestion of foodstuff.

It was also found by the present inventors that EPA, DHA and/or ARA are capable of
10 reducing the effects of IL-4 on intestinal permeability. Hence, one aspect of the present invention provides for a method for the treatment and/or prevention of diseases wherein intestinal IL-4 concentration is increased (e.g. allergic diseases), said method comprising administering an LC-PUFA preferably selected from the group consisting of EPA, DHA and ARA, preferably combined with the present selected
15 oligosaccharides. Hence, the present composition can also be advantageously used in a method for the treatment of atopic dermatitis.

Since the barrier function of newborns has not been fully developed, the present composition can be advantageously administered to young infants, i.e. infants with the
20 age between 0 and 6 months. The composition may be administered to the infant in the form of an infant formula without human milk or admixed with human milk. Hence the present invention also provides for a formula feed comprising human milk and the present composition. The compositions including human milk and the present composition are particularly suitable for feeding premature infants.

25

The present composition is preferably provided as a packaged powder or packaged ready-to-feed formula. To prevent spoilage of the product, packaging size of ready-to-feed formula preferably does not exceed one serving, e.g. preferably does not exceed 500 ml; and packaging size of the present composition in powder form preferably does
30 not exceed 250 servings. Suitable packaging sizes for the powder are 2000 grams or less, preferably per 1000 grams or less.

WO 2005/122790

PCT/NL2004/000444

13

The packaged products provided with labels that explicitly or implicitly direct the consumer towards the use of said product in accordance with one or more of the above or below purposes, are encompassed by the present invention. Such labels may for example make reference to the present method for preventing allergic reaction to food 5 allergens by including wording like "reduced food sensitivity", "improving intestinal tolerability", "improved food tolerance" or similar wording. Similarly, reference to the present method for treating and/or preventing allergy may be made by incorporating terminology equivalent to "improved resistance" or "reduced sensitivity".

10 Formula's

It was found that the present composition can be advantageously applied in food, such as baby food and clinical food. Such food preferably comprises lipid, protein and carbohydrate and is preferably administered in liquid form. The term "liquid food" as used in the present invention includes dry food (e.g. powders) which are accompanied 15 with instructions as to admix said dry food mixture with a suitable liquid (e.g. water).

Hence, the present invention also relates to a nutritional composition which preferably comprises between 5 and 50 en% lipid, between 5 and 50 en% protein, between 15 and 90 en% carbohydrate and the present combination of oligosaccharides and LC-PUFA's. 20 Preferably the present nutritional composition preferably contains between 10 and 30 en% lipid, between 7.5 and 40 en% protein and between 25 and 75 en% carbohydrate (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation).

25 Preferably a combination of vegetable lipids and at least one oil selected from the group consisting of fish oil and omega-3 vegetable, algae or bacterial oil is used.

The proteins used in the nutritional preparation are preferably selected from the group of non-human animal proteins (such as milk proteins, meat proteins and egg proteins), 30 vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein), free amino acids and mixtures thereof. Cow milk derived nitrogen source, particularly cow milk protein proteins such as casein and whey proteins are particularly preferred.

WO 2005/122790

PCT/NL2004/000444

14

A source of digestible carbohydrate may be added to the nutritional formula. It preferably provides about 40% to about 80% of the energy of the nutritional composition. Any suitable (source of) carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, and maltodextrins, and mixtures thereof.

5

The present composition is preferably used as an infant formula and preferably contains 7.5 to 12.5 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat. As the present composition is suitably used to reduce the allergic reaction in an infant, the protein of the infant formula is preferably selected from the group consisting of hydrolyzed milk protein (e.g. hydrolyzed casein or hydrolyzed whey protein), vegetable protein and/or amino acids. The use of these proteins further reduced the allergic reactions of the infant.

15 Stool irregularities (e.g. hard stools, insufficient stool volume, diarrhoea) is a major problem in many babies and ill subjects that receive liquid foods. It was found that stool problems may be reduced by administering the present oligosaccharides in liquid food which have an osmolality between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg.

20 In view of the above, it is also important that the liquid food does not have an excessive caloric density, however still provides sufficient calories to feed the subject. Hence, the liquid food preferably has a caloric density between 0.1 and 2.5 kcal/ml, even more preferably a caloric density of between 0.5 and 1.5 kcal/ml, most preferably between 0.6 and 0.8 kcal/ml.

25

EXAMPLES

Example 1: Effect of LC-PUFA on barrier integrity

30 Monolayers (MC) of intestinal epithelial cell lines T84 (American Type Culture Collection (ATTC), Manassas, USA) were cultured on transwell filters (Corning, Costar BV, The Netherlands) allowing both mucosal and serosal sampling and stimulation of human intestinal epithelial cells. Two weeks post confluence the

WO 2005/122790

PCT/NL2004/000444

15

- monolayers were incubated in the luminal compartment with polyunsaturated fatty acids ARA (arachidonic acid; 5,8,11,14-eicosatetraenoic acid), DHA (cis-4,7,10,13,16,19 docosahexaenoic acid), EPA (eicosapentaenoic acid) or control palmitic (C 16:0) acid (Palm) (Sigma, St. Louis, USA). The latter procedure was chosen to mimic the in vivo administration route of the dietary compounds. Cells were incubated with ARA, DHA, EPA, or palmitic acid for 0, 24, 48 and 72 hr at different concentrations (10 µM and 100 µM). Experiments were performed to evaluate basal barrier integrity. The epithelial barrier function was determined by measuring the transepithelial resistance (TER, Ω.cm²) was measured by epithelial volt-ohm meter (EVOM; World Precision Instruments, Germany) and permeability for 4kD FITC dextran (paracellular permeability marker, Sigma, USA). Resistance (. Epithelial permeability for 4 kDa FITC-dextran was determined as follows. Prior to dextran fluxes the medium was refreshed with culture medium without phenol red for one hour followed by addition of 5 µl (stock 100 mg/ml) 4 kDa FITC-dextran to the luminal compartment. After 30 min incubation 100 µl sample was collected from the serosal compartment and the fluorescent signal measured at excitation wavelength 485 nm and emission 520 nm (FLUOstar Galaxy®, BMG Labtechnologies, USA). FITC-dextran fluxes were calculated as pmol FITC-dextran/cm²/h. Statistical analyses were performed using the ANOVA (SPSS version 10).
- Results of the effect of fatty acids (100 µM) on spontaneous barrier integrity after 72 hr incubation are given in Table 1. Table 1 shows that the LC-PUFA's ARA, EPA and DHA reduce the molecular flux and improve epithelial resistance. In contrast the control experiments show that palmitic acid has the opposite effects, i.e. compromises barrier integrity. These results are indicative for the advantageous use of EPA, DHA and ARA, and in particularly ARA in the composition according to the present invention and for use in a method according to the present invention, e.g. in a method for improving barrier integrity. These result further support the synergistic effects of the present combination of fatty acids and indigestible oligosaccharides.
- Figure 1 shows the time and dose (10µM and 100µM) dependent effects of various fatty acids (palmitic acid, DHA, GLA, and AA) on basal barrier integrity (TER). Figure 1 shows that the LC-PUFA's AA, DHA, and GLA, improve the epithelial barrier integrity as reflected by increased resistance (TER). These results are indicative for the advantageous use of EPA, DHA, GLA and ARA, in particularly ARA, in the

WO 2005/122790

PCT/NL2004/000444

16

composition according to the present invention and for use in a method according to the present invention, i.e. in a method for improving barrier integrity. These results further support the synergistic effects of the present combination of fatty acids and indigestible oligosaccharides.

5

Table 1

Ingredient (LC-PUFA)	Flux	Resistance (TER)
Control	79	1090
Palmitic acid	161	831
DHA	72	1574
ARA	28	1816
EPA	65	1493

Example 2: Effect of LC-PUFA on IL-4 mediated barrier disruption

10 Monolayers (MC) of intestinal epithelial cell lines T84 (ATCC, USA) were cultured on transwell filters (Corning, Costar BV, The Netherlands) allowing both mucosal and serosal sampling and stimulation of human intestinal epithelial cells. Two weeks post confluence the monolayers were incubated in the presence of IL-4 (2 ng/ml, serosal compartment, Sigma, USA) with or without polyunsaturated fatty acids ARA, DHA, GLA, EPA, or control palmitic acid (10 µM or 100 µM, mucosal compartment, Sigma, St. Louis, USA). Cells were pre-incubated with ARA, DHA, EPA, or palmitic acid for 48 hr prior to the IL-4 incubation. The co-incubation of PUFA's and palmetic acid with IL-4 was continued for another 48 hr; while culture medium and additives were changed every 24 hr. The epithelial barrier function was determined by measuring the transepithelial resistance (TER) and permeability as described in example 1. Statistical evaluation was performed as described in example 1.

20 Results of the effect of ARA, DHA, EPA and palmitic acid (100 µM) on IL-4 mediated barrier disruption are given in Table 2. Table 2 shows that the LC-PUFA's ARA, DHA and EPA inhibit the increased flux caused by IL-4. In contrast palmetic acid had a detrimental effect and decreased barrier disruption compared to control. These results are indicative for the advantageous use of ARA, DHA, and EPA in clinical and infant

WO 2005/122790

PCT/NL2004/000444

17

nutrition formulations to prevent or reduce IL-4 mediated barrier disruption, e.g. as occurs in food or cows milk allergy. These result further support the synergistic effects of the present combination of fatty acids and indigestible oligosaccharides.

- 5 Figure 2 gives the time and dose (10 μ M and 100 μ M) dependent protective effects of various FA's (palmitic acid, DHA, GLA, and AA) on IL-4 mediated barrier destruction (Flux). Figure 2 shows that ARA, DHA and GLA protect against IL-4 mediated barrier disruption as reflected by decreased 4kD dextran flux. These results are indicative for the advantageous use of ARA, DHA and GLA in clinical and infant nutrition
 10 formulations to prevent or reduce IL-4 mediated barrier disruption, e.g. as occurs in food or cows milk allergy. These result further support the synergistic effects of the present combination of fatty acids and indigestible oligosaccharides.

Table 2

<u>Ingredient (LC-PUFA)</u>	<u>IL-4 Flux</u>	<u>IL-4 TER</u>
Control	582	374
Palmitic acid	777	321
DHA	271	547
ARA	218	636
EPA	228	539

15

Example 3: Effect of oligosaccharides on acetate production

- Micro-organisms were obtained from fresh faeces from bottle fed babies. Fresh faecal material from babies ranging 1 to 4 month of age was pooled and put into preservative medium within 2 h. As substrate either prebiotics (TOS; TOS/inulin (HP) mixture in a 9/1 (w/w) ratio; inulin; oligofructose(OS)/inulin mixture in a 1/1 (w/w) ratio, or none (blanc) were used. The transgalactooligosaccharides (TOS) were obtained from Vivinal GOS, Borculo Domo Ingredients, Zwolle, The Netherlands and comprises as
 20 indigestible oligosaccharides: 33 wt.% disaccharides, 39 wt.% trisaccharides, 18 wt.% tetrasaccharides, 7 wt.% pentasaccharides and 3 wt.% hexa-, hepta- en octasaccharides.
 25 The inulin (HP) Orafti active food ingredients, Tienen, Belgium, i.e. Raftiline HP®,

WO 2005/122790

PCT/NL2004/000444

18

with an average DP of 23. **Media:** McBain & MacFarlane medium: buffered peptone water 3.0g/l, yeast extract 2.5 g/l, mucin (brush borders) 0.8 g/l, tryptone 3.0g/l, L-Cysteine-HCl 0.4 g/l, bile salts 0.05 g/l, K₂HPO₄.3H₂O 2.6 g/l, NaHCO₃ 0.2 g/l, NaCl 4.5 g/l, MgSO₄.7H₂O 0.5 g/l, CaCl₂ 0.228 g/l, FeSO₄.7H₂O 0.005 g/l. Fill 500 ml

5 Scott bottles with the medium and sterilized 15 minutes at 121 °C. **Buffered medium:** K₂HPO₄.3H₂O 2.6 g/l, NaHCO₃ 0.2 g/l, NaCl 4.5 g/l, MgSO₄.7H₂O, 0.5 g/l, CaCl₂ 0.228 g/l, FeSO₄.7H₂O 0.005 g/l. Adjust to pH 6.3 ± 0.1 with K₂HPO₄ or NaHCO₃. Fill 500ml Scott bottles with the medium and sterilized 15 minutes at 121 °C.

10 **Preservative medium:** Buffered peptone 20.0 g/l, L-Cysteine-HCl 0.5 g/l, Sodium thioglycollate 0.5 g/l, resazurine tablet 1 per litre, adjust to pH 6.7 ± 0.1 with 1 M NaOH or HCl. Boiled in microwave. Serum bottles were filled with 25 ml medium and sterilized for 15 minutes at 121 °C.

15 Fresh faecal samples were mixed with preservative medium and stored for several hours at 4 °C. The preserved solution of faeces was centrifuged at 13,000 rpm for 15 minutes, supernatant removed and faeces mixed with McBain & Mac Farlane medium in a weight ratio of 1:5. Of this faecal suspension 3 ml were combined with 85 mg glucose or prebiotic or with no addition (blanc) in a bottle and mixed thoroughly. A t=0 sample was withdrawn (0.5 ml). 2.5 ml of the resulting suspension is brought in a dialysis tube in a 60 ml bottle filled with 60 ml of the buffered medium. The bottle was 20 closed well and incubated at 37°C. Samples were taken from the dialysis tube (0.2 ml) or dialysis buffer (1.0 ml) with a hypodermic syringe after 3, 24, and 48 hours and immediately put it on ice to stop fermentation. The experiment was carried out using the following samples:

- 25 1) 85mg TOS
2) 85 mg inulin
3) 85mg TOS/inulin in a ratio of 9/1 (w/w) and
4) 85mg OS/inulin in a ratio of 1/1 (w/w).

30 SCFA (acetate, propionate, butyrate) were quantitated using a Varian 3800 gas chromatograph (GC) (Varian Inc., Walnut Creek, U.S.A.) equipped with a flame ionisation detector. 0.5 µl of the sample was injected at 80 °C in the column (Stabilwax, 15 x 0.53 mm, film thickness 1.00 µm, Restek Co., U.S.A.) using helium as a carrier gas (3.0 psi). After injection of the sample, the oven was heated to 160 °C at a speed of

WO 2005/122790

PCT/NL2004/000444

19

16 °C/min, followed by heating to 220 °C at a speed of 20 °C/min and finally maintained at 220 °C for 1.5 minutes. The temperature of the injector and detector was 200 °C. 2-ethylbutyric acid was used as an internal standard.

Figure 3 depicts the absolute (Figure 3A) and relative SCFA profile (Figure 3B) resulting from fermenting the different oligosaccharides. Figure 3A shows that a mixture of two different oligosaccharides (TOS/Inulin), wherein the two distinct oligosaccharides have a homology in monose units below 90 and a different chain length results in a significantly and synergistically increased amount of SCFA (particularly acetate) per gram fiber than single components. Figure 3B shows that the addition of a combination of TOS/Inulin favored a higher proportion of the beneficial acetate (B). The acetate production in vivo translates to improved mucus production by goblet cells and a measure for intestinal mucus layer thickness (see example 4). These results are indicative for the advantageous use of the present composition.

15 Example 4: Effects of SCFA on mucus production.

Monolayers of intestinal epithelial T84 cells (ATCC, USA) cells were cultured in 24 or 96 wells tissue culture plates (Corning B.V.). T84 were incubated with the short chain fatty acids acetate, propionate and butyrate (SCFA, Merck, USA) for 24 h in a concentration range of 0.025-4.0 mM. Supernatants and/or cells were collected and MUC-2 (mucin) expression determined. A dot blot technique was used to determine MUC-2 expression in the cell cultures, since mucins are extremely large glycoproteins (over 500 kDa) which makes them difficult to handle in western blotting techniques. The method was validated using pre-immune serum (T84 stained negative), CCD-18Co (ATCC, USA) negative control cells and bovine serum albumin (BSA). Cell samples were collected in Laemmli (protein isolation buffer) and protein determination performed using a microprotein assay (Biorad, USA) according to the manufacturers protocol. Samples (0.3-0.7-1.0 µg/2 µl) were dotted on nitrocellulose membranes (Schleicher & Schuell, Germany). Membranes were blocked in TBST/5% Protivar (Nutricia, The Netherlands) followed by 1 h incubation with anti-MUC-2 antibody (kindly donated by Dr. Einerhand, Erasmus University, Rotterdam, The Netherlands). After washing, blots were incubated with goat anti-rabbit-HRP (Santacruz Biotechnology, USA) and for substrate detection ECL (Roche Diagnostics, The Netherlands) was used. Densitometry was performed using the Lumi-Imager

WO 2005/122790

PCT/NL2004/000444

20

(Boehringer Mannheim B.V., The Netherlands) and the signal was expressed in light units (BLU). BLU's were also expressed relative to control incubations (%BLU). To compare the stimulatory effect of SCFA on MUC-2 expression basal MUC-2 expression levels were deducted.

- 5 Figure 4 shows the differential effects of SCFA (acetate, propionate, butyrate) on MUC-2 expression in intestinal epithelial cells (MC T84) and epithelial-mesenchymal cell co-cultures (CC T84). Figure 2 also shows that acetate is more potent in stimulating MUC-2 expression (mucus production) as compared to propionate and butyrate. Hence, the present combination of oligosaccharides (which was shown to
10 increase acetate production (see example 3)) is particularly useful for stimulating mucus production and can be advantageously used in a method for stimulating barrier integrity.

Example 5: Infant milk formula I

- 15 Ingredients (per liter), energy 672 Kcal; Protein 15 g; Whey: Casein ratio 60:40; Fat 36 g; Carbohydrate 72 g; Vitamin A 750 RE; Mixed natural carotids 400 IU; Vitamin D 10.6 mcg; Vitamin F 7.4 mg; Vitamin K 67.0 mcg; Vitamin B.sub.1 (thiamin) 1000 mcg; Vitamin B.sub.2 (riboflavin) 1500 mcg; Vitamin B.sub.6 (pyridoxine) 600 mcg; Vitamin B.sub.12 (cyanacobalmine) 2.0 mcg; Niacin 9.0 mcg; Folic Acid 80 mcg;
20 Pantethenic Acid 3000 mcg; Biotin 90 mcg; Vitamin C (ascorbic acid) 90 mg; Choline 100 mg; Inositol 33 mg; Calcium 460 Mg; Phosphorous 333 Mg; Magnesium 64 Mg; Iron 8.0 Mg ; Zinc 6.0 Mg; Manganese 50 mcg; Copper 560 mcg; Iodine 100 mcg; Sodium 160 mg; Potassium 650 mg; Chloride 433 mg and Selenium 14 mcg; wherein the fat content provides includes 3 gram fish oil and 3 grams 40% arachidonic acid oil
25 (DSM Food Specialties, Delft, Netherlands); further comprising 4 gram transgalactooligosaccharides Elix'orTM (Borculo Domo Ingredients, Netherlands) and 4 gram RaftilineTM (Orafti Active Food Ingredients, Belgium).

WO 2005/122790

PCT/NL2004/000444

21

CLAIMS

1. Use of polyunsaturated fatty acids for the manufacture of a composition for use in a method for stimulating intestinal barrier integrity, said method comprising administering to a mammal a composition comprising:
 - a. eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), wherein the content of long chain polyunsaturated fatty acid with 20 and 22 carbon atoms does not exceed 15 wt.% of the total fat content; and
 - b. at least two distinct oligosaccharides (OL1 and OL2), wherein the two distinct oligosaccharides have a homology in monose units below 90 %.
2. Nutritional composition comprising:
 - a. EPA, DHA and ARA, wherein the content of long chain polyunsaturated fatty acid with 20 and 22 carbon atoms does not exceed 15 wt.% of the total fat content; and
 - b. at least two distinct oligosaccharides (OL1 and OL2), wherein the two distinct oligosaccharides have a homology in monose units below 90 %.
3. Composition according to claim 2, comprising galactooligosaccharide and a fructan selected from the group consisting of fructooligosaccharides, inulin and mixtures thereof.
4. Composition according to claim 2 or 3, wherein at least 10 wt.% of the oligosaccharide has a degree of polymerisation (DP) of 2 to 5 and at least 5 wt.% has a DP of between 10 and 60.
5. Composition according to any one claims 2-4, further comprising an acidic oligosaccharide, preferably an uronic acid polymer with a DP between 2 and 60.
- 30 6. Composition according to any one of claims 2-5, comprising 7.5 to 12.5 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat, wherein said protein comprises a member selected from the group consisting of hydrolyzed milk protein, vegetable protein and/or amino acids.

WO 2005/122790

PCT/NL2004/000444

22

7. Composition according to any one of claims 2-6, said composition having a caloric content of 0.6 to 0.8 kcal/ml; an osmolality of 50 to 500 mOsm/kg; and a viscosity below 50 mPas.

5

8. Composition according to any one of claims 2-7, suitable for feeding an infant, wherein:

- a. the content of long chain polyunsaturated fatty acid is below 3 wt.% of the total fat content;
- 10 b. the omega-3 long chain polyunsaturated fatty acid is below 1 wt.% of the total fat content;
- c. the omega-6 long chain polyunsaturated fatty acid is below 2 wt.% of the total fat content;
- d. the ARA content is below 1 wt.% of the total fat content; and
- 15 e. the ratio EPA/DHA is 1 or below.

9. Composition according to any one of claims 2-8, for use as a medicament.

10. Use of a composition according to any one of claims 2-8 for the manufacture of a
20 medicament for use in a method for the treatment or prevention of allergy, said method comprising administering to a mammal the composition according to any one of claims 2-8.

11. Use of a composition according to any one of claims 2-8 for the manufacture of a
25 medicament for use in a method for the treatment or prevention of diarrhea, said method comprising administering to a mammal the composition according to any one of claims 2-8.


WO 2005/122790

PCT/NL2004/000444


1/4

Fig 1a

Effect PUFA (n=3) on basal barrier integrity (TER)

*Fig 1b*



Effect PUFA (n=3) on basal barrier integrity (TER)



WO 2005/122790

PCT/NL2004/000444



2/4

Fig 2a*Fig 2b*

WO 2005/122790

PCT/NL2004/000444


3/4

Fig 3a*Fig 3b*

WO 2005/122790

PCT/NL2004/000444

4/4

Fig 4

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/NL2004/000444

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A23L1/29 A23L1/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 468 987 B1 (DEMICHÈLE STEPHEN JOSEPH ET AL) 22 October 2002 (2002-10-22) the whole document	1-11
A	WO 01/78530 A (ABBOTT LABORATORIES) 25 October 2001 (2001-10-25) cited in the application the whole document	1-11
A	EP 1 155 627 A (BELOVO EGGS & EGG PRODUCTS) 21 November 2001 (2001-11-21) the whole document	1-11

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

23 February 2005

Date of mailing of the international search report

03/03/2005

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Adechy, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l	Domestic Application No
PCT/NL2004/000444	

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 6468987	B1	22-10-2002		US 5952314 A US 5780451 A AT 212194 T AU 689555 B2 AU 1884495 A CA 2187628 A1 DE 69525150 D1 DE 69525150 T2 DK 754001 T3 EP 0754001 A1 ES 2171535 T3 HK 1011914 A1 NZ 281878 A PT 754001 T WO 9526646 A1		14-09-1999 14-07-1998 15-02-2002 02-04-1998 23-10-1995 12-10-1995 14-03-2002 05-09-2002 13-05-2002 22-01-1997 16-09-2002 14-02-2003 24-02-1997 31-07-2002 12-10-1995
WO 0178530	A	25-10-2001		AU 5533701 A CA 2405822 A1 CN 1436048 T EP 1272058 A2 JP 2004518609 T MX PA02010085 A WO 0178530 A2 US 2003190363 A1 US 2002004527 A1 US 2002045660 A1		30-10-2001 25-10-2001 13-08-2003 08-01-2003 24-06-2004 15-10-2003 25-10-2001 09-10-2003 10-01-2002 18-04-2002
EP 1155627	A	21-11-2001		EP 1155627 A1 AU 5996501 A WO 0187091 A1 CA 2409194 A1 CN 1429078 T EP 1282367 A1 JP 2003533199 T US 2004022924 A1 ZA 200208718 A		21-11-2001 26-11-2001 22-11-2001 22-11-2001 09-07-2003 12-02-2003 11-11-2003 05-02-2004 06-08-2003